Loading…

Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study

Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72...

Full description

Saved in:
Bibliographic Details
Published in:The European journal of contraception & reproductive health care 2014-02, Vol.19 (1), p.29-38
Main Authors: Short, Mary, Dallay, Dominique, Omokanye, Salmon, Stauch, Kathrin, Inki, Pirjo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3
cites cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3
container_end_page 38
container_issue 1
container_start_page 29
container_title The European journal of contraception & reproductive health care
container_volume 19
creator Short, Mary
Dallay, Dominique
Omokanye, Salmon
Stauch, Kathrin
Inki, Pirjo
description Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented. Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively. Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.
doi_str_mv 10.3109/13625187.2013.862230
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_13625187_2013_862230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3216695491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqXwDxCyxIVDvdhj54tD0aoqH1IlLnCOHGeydeW1g-1slX-Pw7YIOPTkOTzP6xm9RfGas43grH3PRQUlb-oNMC42TQUg2JPilMtaUFY38DTPGaErc1K8iPGWZVCK6nlxAhKatoTmtDhstcYpqd5YkxbiR2K921Glk3G7czIFv8OYZ-qdXYj2LgW1CsY7Yhy5moOf8APZknTn6YIqrEqcMPsHPCfOO2pcwnBAtzrKkpjmYXlZPBuVjfjq_j0rfny6-n75hV5_-_z1cntNtZRVon0plO7rSusK2hI5DGwQrZa1Ag3QK6YVYMvbQTGQyHAUQpYthx40l-OgxFnx7pibt_o550u6vYkarVUO_Rw7LlspmKhZndG3_6G3fg55499UDQ0AbzIlj5TOZ8aAYzcFs1dh6Tjr1l66h166tZfu2EvW3tyHz_0ehz_SQxEZ-HgEjBt92Ks7H-zQJbVYH8agnDZxjX_0i4t_Em5Q2XSjVcC_Dnks4Bez8rE1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497282218</pqid></control><display><type>article</type><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</creator><creatorcontrib>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</creatorcontrib><description>Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented. Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively. Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</description><identifier>ISSN: 1362-5187</identifier><identifier>EISSN: 1473-0782</identifier><identifier>DOI: 10.3109/13625187.2013.862230</identifier><identifier>PMID: 24289528</identifier><identifier>CODEN: ECRCFK</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Adult ; Birth control ; Continuation ; Contraception - methods ; Contraceptive Agents, Female - therapeutic use ; Desogestrel - therapeutic use ; Device Removal - statistics &amp; numerical data ; Drug Implants - therapeutic use ; Etonogestrel releasing-subdermal implant ; Female ; France ; Humans ; Intrauterine devices ; Intrauterine Devices, Medicated - utilization ; Ireland ; IUD ; Levonorgestrel - therapeutic use ; Levonorgestrel releasing-intrauterine system ; Long-acting reversible contraceptives ; Longitudinal Studies ; Menstruation ; Middle Aged ; Patient Acceptance of Health Care ; Prospective Studies ; Satisfaction ; Slovakia ; Transplants &amp; implants ; United Kingdom ; Womens health ; Young Adult</subject><ispartof>The European journal of contraception &amp; reproductive health care, 2014-02, Vol.19 (1), p.29-38</ispartof><rights>2014 The European Society of Contraception and Reproductive Health 2014</rights><rights>Copyright Taylor &amp; Francis Ltd. Feb 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</citedby><cites>FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24289528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Short, Mary</creatorcontrib><creatorcontrib>Dallay, Dominique</creatorcontrib><creatorcontrib>Omokanye, Salmon</creatorcontrib><creatorcontrib>Stauch, Kathrin</creatorcontrib><creatorcontrib>Inki, Pirjo</creatorcontrib><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><title>The European journal of contraception &amp; reproductive health care</title><addtitle>Eur J Contracept Reprod Health Care</addtitle><description>Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented. Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively. Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</description><subject>Adult</subject><subject>Birth control</subject><subject>Continuation</subject><subject>Contraception - methods</subject><subject>Contraceptive Agents, Female - therapeutic use</subject><subject>Desogestrel - therapeutic use</subject><subject>Device Removal - statistics &amp; numerical data</subject><subject>Drug Implants - therapeutic use</subject><subject>Etonogestrel releasing-subdermal implant</subject><subject>Female</subject><subject>France</subject><subject>Humans</subject><subject>Intrauterine devices</subject><subject>Intrauterine Devices, Medicated - utilization</subject><subject>Ireland</subject><subject>IUD</subject><subject>Levonorgestrel - therapeutic use</subject><subject>Levonorgestrel releasing-intrauterine system</subject><subject>Long-acting reversible contraceptives</subject><subject>Longitudinal Studies</subject><subject>Menstruation</subject><subject>Middle Aged</subject><subject>Patient Acceptance of Health Care</subject><subject>Prospective Studies</subject><subject>Satisfaction</subject><subject>Slovakia</subject><subject>Transplants &amp; implants</subject><subject>United Kingdom</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>1362-5187</issn><issn>1473-0782</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoqXwDxCyxIVDvdhj54tD0aoqH1IlLnCOHGeydeW1g-1slX-Pw7YIOPTkOTzP6xm9RfGas43grH3PRQUlb-oNMC42TQUg2JPilMtaUFY38DTPGaErc1K8iPGWZVCK6nlxAhKatoTmtDhstcYpqd5YkxbiR2K921Glk3G7czIFv8OYZ-qdXYj2LgW1CsY7Yhy5moOf8APZknTn6YIqrEqcMPsHPCfOO2pcwnBAtzrKkpjmYXlZPBuVjfjq_j0rfny6-n75hV5_-_z1cntNtZRVon0plO7rSusK2hI5DGwQrZa1Ag3QK6YVYMvbQTGQyHAUQpYthx40l-OgxFnx7pibt_o550u6vYkarVUO_Rw7LlspmKhZndG3_6G3fg55499UDQ0AbzIlj5TOZ8aAYzcFs1dh6Tjr1l66h166tZfu2EvW3tyHz_0ehz_SQxEZ-HgEjBt92Ks7H-zQJbVYH8agnDZxjX_0i4t_Em5Q2XSjVcC_Dnks4Bez8rE1</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Short, Mary</creator><creator>Dallay, Dominique</creator><creator>Omokanye, Salmon</creator><creator>Stauch, Kathrin</creator><creator>Inki, Pirjo</creator><general>Informa Healthcare</general><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201402</creationdate><title>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</title><author>Short, Mary ; Dallay, Dominique ; Omokanye, Salmon ; Stauch, Kathrin ; Inki, Pirjo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Birth control</topic><topic>Continuation</topic><topic>Contraception - methods</topic><topic>Contraceptive Agents, Female - therapeutic use</topic><topic>Desogestrel - therapeutic use</topic><topic>Device Removal - statistics &amp; numerical data</topic><topic>Drug Implants - therapeutic use</topic><topic>Etonogestrel releasing-subdermal implant</topic><topic>Female</topic><topic>France</topic><topic>Humans</topic><topic>Intrauterine devices</topic><topic>Intrauterine Devices, Medicated - utilization</topic><topic>Ireland</topic><topic>IUD</topic><topic>Levonorgestrel - therapeutic use</topic><topic>Levonorgestrel releasing-intrauterine system</topic><topic>Long-acting reversible contraceptives</topic><topic>Longitudinal Studies</topic><topic>Menstruation</topic><topic>Middle Aged</topic><topic>Patient Acceptance of Health Care</topic><topic>Prospective Studies</topic><topic>Satisfaction</topic><topic>Slovakia</topic><topic>Transplants &amp; implants</topic><topic>United Kingdom</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Short, Mary</creatorcontrib><creatorcontrib>Dallay, Dominique</creatorcontrib><creatorcontrib>Omokanye, Salmon</creatorcontrib><creatorcontrib>Stauch, Kathrin</creatorcontrib><creatorcontrib>Inki, Pirjo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of contraception &amp; reproductive health care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Short, Mary</au><au>Dallay, Dominique</au><au>Omokanye, Salmon</au><au>Stauch, Kathrin</au><au>Inki, Pirjo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study</atitle><jtitle>The European journal of contraception &amp; reproductive health care</jtitle><addtitle>Eur J Contracept Reprod Health Care</addtitle><date>2014-02</date><risdate>2014</risdate><volume>19</volume><issue>1</issue><spage>29</spage><epage>38</epage><pages>29-38</pages><issn>1362-5187</issn><eissn>1473-0782</eissn><coden>ECRCFK</coden><abstract>Abstract Objectives To compare two-year continuation rates and user satisfaction with the levonorgestrel releasing-intrauterine system (LNG-IUS) and the etonogestrel releasing-subdermal implant (ENG implant) in women in Europe. Methods This prospective, non-interventional study was undertaken at 72 sites in France (n = 61), Great Britain (n = 2), Ireland (n = 3) and Slovakia (n = 6). Women opting to switch their method of contraception to the LNG-IUS or the ENG implant were followed-up over 24 months to document continuation and satisfaction with their chosen contraceptive method. Reasons for discontinuation were documented. Results The data analysed were based on 363 women (LNG-IUS [n = 247] and ENG implant [n = 116]), aged 20 to 45 years, with at least one follow-up visit after contraceptive placement. The documented cumulative continuation rate was 82% in the LNG-IUS group and 67% in the ENG implant group at 24 months. The documented discontinuation rates were 13% and 17%, respectively. Bleeding problems were cited as reason for discontinuation in 4% and 11% of women in the LNG-IUS and ENG implant groups, respectively. Conclusions The LNG-IUS is associated with higher continuation rates and user satisfaction than the ENG implant in this study of women in Europe, though the groups were not similar in all respects. Bleeding problems with the ENG implant account for most of the reasons for discontinuing its use.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>24289528</pmid><doi>10.3109/13625187.2013.862230</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1362-5187
ispartof The European journal of contraception & reproductive health care, 2014-02, Vol.19 (1), p.29-38
issn 1362-5187
1473-0782
language eng
recordid cdi_crossref_primary_10_3109_13625187_2013_862230
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Adult
Birth control
Continuation
Contraception - methods
Contraceptive Agents, Female - therapeutic use
Desogestrel - therapeutic use
Device Removal - statistics & numerical data
Drug Implants - therapeutic use
Etonogestrel releasing-subdermal implant
Female
France
Humans
Intrauterine devices
Intrauterine Devices, Medicated - utilization
Ireland
IUD
Levonorgestrel - therapeutic use
Levonorgestrel releasing-intrauterine system
Long-acting reversible contraceptives
Longitudinal Studies
Menstruation
Middle Aged
Patient Acceptance of Health Care
Prospective Studies
Satisfaction
Slovakia
Transplants & implants
United Kingdom
Womens health
Young Adult
title Acceptability of long-acting, progestin-only contraception in Europe: A two-year prospective, non-interventional study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A11%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acceptability%20of%20long-acting,%20progestin-only%20contraception%20in%20Europe:%20A%20two-year%20prospective,%20non-interventional%20study&rft.jtitle=The%20European%20journal%20of%20contraception%20&%20reproductive%20health%20care&rft.au=Short,%20Mary&rft.date=2014-02&rft.volume=19&rft.issue=1&rft.spage=29&rft.epage=38&rft.pages=29-38&rft.issn=1362-5187&rft.eissn=1473-0782&rft.coden=ECRCFK&rft_id=info:doi/10.3109/13625187.2013.862230&rft_dat=%3Cproquest_cross%3E3216695491%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-b53acb76cc6295e12d0d39c47a2c22ba0ca2e919da024e0ef3345912b2c14fda3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1497282218&rft_id=info:pmid/24289528&rfr_iscdi=true